Jupiter Wellness, Inc. - JUPW STOCK NEWS

Jupiter Wellness (Nasdaq:JUPW) announced the recent launch meetings for its Photocil products in India, hosted by Eris Oaknet and Cosmofix. These meetings featured presentations from top dermatologists and were aimed at introducing the approved product 'Photofirst' in the Indian market. The product, which targets skin conditions like vitiligo, received approval from the CDSCO, analogous to the FDA in the U.S. The CEO emphasized the importance of this launch in achieving profitability for 2023, alongside potential significant licensing fees.

Jupiter Wellness (Nasdaq: JUPW) reported a significant revenue increase of $1,569,925 for Q3 2022, up from $687,928 in Q3 2021. The company's operating expenses decreased to $2,196,502 compared to $3,609,223 in the same quarter last year. Although net losses reduced to $2,232,426 from $4,808,430, the company anticipates continued revenue growth and plans to spin off its SRM division by year-end. The subsidiary also secured $3.6 million in guaranteed orders from major amusement parks.

Jupiter Wellness (Nasdaq:JUPW) has announced the re-opening of enrollment in a clinical trial to evaluate JW-100, a cannabinoid topical cream, against Pfizer's FDA-approved EUCRISA for eczema treatment. After addressing formulation stability issues, the company aims for complete patient enrollment by December 2022. CEO Brian John expressed optimism about JW-100's potential efficacy compared to established products that generate significant revenue. The second phase of the trial is anticipated for completion in Q1 2023.

Jupiter Wellness (Nasdaq: JUPW) announced plans to spin off Caring Brands, Inc. by issuing a 40% dividend in the form of digital securities to shareholders. The record date is set for late November 2022. Jupiter will retain 60% of Caring Brands, which focuses on CBD-based therapeutics. The dual listing on Upstream aims to enhance liquidity and attract a global investor base. Approval for the listing is pending. This initiative reflects the company's strategy to boost shareholder value and streamline operations.

Jupiter Wellness (Nasdaq: JUPW) has announced its entry into the psoriasis and vitiligo market in India, with a population of 1.4 billion. The CDSCO has approved its Photocil product, marketed as PhotoFirst in India, which filters UV rays for therapeutic use. The product's commercial launch is expected in Q1 2023 following a licensing agreement for distribution in 31 countries. Key team members will present at an International Speaker Program in Mumbai on November 12, 2022, highlighting advancements in phototherapy.

Jupiter Wellness, Inc. (Nasdaq:JUPW) has launched a triple-blinded clinical trial to explore a potential treatment for tinnitus, particularly post-acute COVID-19 tinnitus affecting up to 15% of COVID-19 survivors. The study examines dopamine receptor modulation as a treatment method, a novel approach resulting from the company’s recent research. This initiative follows a patent filing related to the treatment of tinnitus. The company's ongoing focus includes developing wellness products for various health issues, funded through OTC sales and research agreements.

Jupiter Wellness (NASDAQ: JUPW) announced on September 29, 2022, it has initiated the application process for a dual listing on Upstream, a platform for digital securities and NFTs. This move aims to attract a global investor base by allowing trades using various payment methods including USDC digital currency. CEO Brian John highlighted the dual listing as a means to enhance liquidity and provide added value to shareholders. The listing is subject to MERJ's approval, with Jupiter already meeting the necessary listing standards.

Jupiter Wellness, Inc. (NASDAQ:JUPW) has received a notice of allowance for patent application No. 16/747,685 from the USPTO, concerning Minoxidil Adjuvant Therapies. This patent enhances the treatment of alopecia by increasing the response to minoxidil through the up-regulation of sulfotransferases in hair follicles. The company has licensed this technology to Taisho Pharmaceutical Co. Ltd, Japan's largest marketer of minoxidil. Dr. Glynn Wilson, Chief Scientific Officer, stated that this patent strengthens their position in the hair loss market.

Jupiter Wellness (NASDAQ:JUPW) announced an exclusive licensing agreement with Rejoy, Inc. to develop prescription products aimed at treating nipple neuropathies in breast cancer patients. The licensed technology includes patents and formulations, with early clinical studies indicating improvements in nipple sensitivity and sexual health. The new product, named JW-500, will be part of Jupiter's clinical pipeline, with plans to seek FDA approval via the expedited 505 (b)(2)